Favipiravir Observational Study Interim Report 3

Favipiravir Observational Study Group, Fujita Health University, Apr 2021
Retrospective analysis of favipiravir use in 10,986 hospitalized patients, including analysis of changes in clinical status and side effects. Common adverse events were uric acid level increase and liver function enzyme increase. Authors note that early embryonic lethality and teratogenicity due to favipiravir have been observed in animal models, that pregnant women must be excluded, and that all patients and partners should practice effective contraception.
Potential risks of favipiravir include kidney injury1-3, liver injury2-5, cardiovascular events5,6, pulmonary toxicity6,7, and mutagenicity, carcinogenicity, teratogenicity, embryotoxicity, and the creation of dangerous variants8-14.
Favipiravir Observational Study Group et al., 19 Apr 2021, preprint, 1 author.
Abstract: Favipiravir Observational Study Interim Report 3 (as of February 28, 2021) Favipiravir Observational Study Group, Fujita Health University
Late treatment
is less effective